Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy
Launched by JINGEN XIA · Mar 17, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new inhalation therapy using ultrasound rock salt aerosol for patients with conditions like COPD (Chronic Obstructive Pulmonary Disease), asthma, and chronic bronchitis. The study aims to understand how well these tiny salt particles can reach the lungs when inhaled, comparing the effectiveness of this new method to a common device called a nebulizer. Researchers will use advanced imaging technology to track where these particles go in the lungs, helping to ensure that the new therapy could be beneficial for patients with respiratory issues.
To participate in this study, volunteers must be healthy or have chronic airway diseases that require nebulization therapy. However, individuals under 18 years old, those with certain health conditions (like severe liver or kidney problems), or anyone who is allergic to radioactive materials cannot join. Participants will inhale small amounts of these aerosol particles, and through imaging, researchers will study how they spread within the lungs. This research is important as it could help develop better treatments for people with breathing difficulties in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy volunteers; Patients with chronic airway disease requiring nebulization therapy.
- Exclusion Criteria:
- • Those aged \< 18 years; Refusing to participate in the study; Patients requiring invasive ventilator assisted breathing; Patients with artificial airways. Patients with chronic liver and kidney function injury. Allergic to radioactive elements.
About Jingen Xia
Jingen Xia is a distinguished clinical trial sponsor specializing in the design, management, and execution of innovative clinical research studies. With a commitment to advancing medical science, Jingen Xia leverages cutting-edge methodologies and a patient-centric approach to ensure the highest standards of safety and efficacy in trial implementation. The organization collaborates with a network of leading healthcare professionals and institutions to facilitate groundbreaking research across various therapeutic areas, ultimately aiming to enhance patient outcomes and contribute to the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Jingen Xia, M.D
Study Director
China-Japan Friendship Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported